Tags

Type your tag names separated by a space and hit enter

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
Mov Disord. 2017 Nov; 32(11):1636-1640.MD

Abstract

BACKGROUND

Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD.

OBJECTIVES

To evaluate vitamin D levels in a population at risk for developing PD.

METHODS

Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity.

RESULTS

Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake.

CONCLUSIONS

Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin D insufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis. © 2017 International Parkinson and Movement Disorder Society.

Authors+Show Affiliations

Parkinson's Disease Research, Education, and Clinical Center (PADRECC), Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA. Parkinson's Associated Risk Study, New Haven, Connecticut, USA.Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Parkinson's Associated Risk Study, New Haven, Connecticut, USA.Eli Lilly and Company, New York, New York, USA.Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Parkinson's Associated Risk Study, New Haven, Connecticut, USA.Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

28906025

Citation

Fullard, Michelle E., et al. "Vitamin D in the Parkinson Associated Risk Syndrome (PARS) Study." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 32, no. 11, 2017, pp. 1636-1640.
Fullard ME, Xie SX, Marek K, et al. Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. Mov Disord. 2017;32(11):1636-1640.
Fullard, M. E., Xie, S. X., Marek, K., Stern, M., Jennings, D., Siderowf, A., Willis, A. W., & Chen-Plotkin, A. S. (2017). Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. Movement Disorders : Official Journal of the Movement Disorder Society, 32(11), 1636-1640. https://doi.org/10.1002/mds.27127
Fullard ME, et al. Vitamin D in the Parkinson Associated Risk Syndrome (PARS) Study. Mov Disord. 2017;32(11):1636-1640. PubMed PMID: 28906025.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. AU - Fullard,Michelle E, AU - Xie,Sharon X, AU - Marek,Ken, AU - Stern,Matthew, AU - Jennings,Danna, AU - Siderowf,Andrew, AU - Willis,Allison W, AU - Chen-Plotkin,Alice S, Y1 - 2017/09/14/ PY - 2017/04/26/received PY - 2017/06/02/revised PY - 2017/06/18/accepted PY - 2017/9/15/pubmed PY - 2018/6/26/medline PY - 2017/9/15/entrez KW - Parkinson's disease KW - cognition KW - cohort studies KW - vitamin D SP - 1636 EP - 1640 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 32 IS - 11 N2 - BACKGROUND: Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD. OBJECTIVES: To evaluate vitamin D levels in a population at risk for developing PD. METHODS: Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity. RESULTS: Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake. CONCLUSIONS: Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin D insufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis. © 2017 International Parkinson and Movement Disorder Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/28906025/Vitamin_D_in_the_Parkinson_Associated_Risk_Syndrome__PARS__study_ L2 - https://doi.org/10.1002/mds.27127 DB - PRIME DP - Unbound Medicine ER -